Publication:
Antirheumatic drugs in reproduction, pregnancy, and lactation: a systematic literature review informing the 2024 update of the EULAR recommendations.

cris.virtualsource.author-orcide7f63ed0-a80a-428b-a469-6aa9848752a9
cris.virtualsource.author-orcid8a4f952d-1fbf-40b4-8ebf-440ef66fd7df
cris.virtualsource.author-orcid5f4011fa-bad0-450f-a7ff-8b5307b9929a
datacite.rightsopen.access
dc.contributor.authorPluma, Andrea
dc.contributor.authorHamroun, Sabrina
dc.contributor.authorRüegg, Linda
dc.contributor.authorCecchi, Irene
dc.contributor.authorKramer, Malte
dc.contributor.authorPerez-Garcia, Luis Fernando
dc.contributor.authorRivero, Tania
dc.contributor.authorFinckh, Axel
dc.contributor.authorMeissner, Yvette
dc.contributor.authorFörger, Frauke
dc.date.accessioned2025-05-08T15:30:05Z
dc.date.available2025-05-08T15:30:05Z
dc.date.issued2025-09
dc.description.abstractObjectives This study aimed to summarise and update evidence to inform the 2024 update of the European Alliance of Associations for Rheumatology recommendations for the use of antirheumatic drugs in reproduction, pregnancy, and lactation.Methods A systematic literature review (SLR) was performed, including keywords on reproduction, adverse pregnancy outcomes (APOs), and lactation. Two appraised SLRs were the basis for the SLR on drug safety in men. If sufficient data were available, a meta-analysis was performed on maternal drug exposure and the risk of APOs.Results Of 6680 screened articles, 255 were included in the final analysis. In pregnancy, most evidence was available for biologic disease-modifying antirheumatic drugs (bDMARDs). Meta-analyses with adjusted risk estimates did not reveal APOs or serious infant infections to be associated with tumour necrosis factor inhibitor (TNFi) use. Data on non-TNFi bDMARDs did not raise concerns. In bDMARD-exposed infants, no serious adverse effects to rotavirus live vaccination were reported. Safety of Bacille Calmette-Guérin vaccination in TNFi-exposed infants could be a concern in the first 6 months of life. Regarding oral glucocorticoids, the SLR and meta-analysis using adjusted risk estimates found a dose-dependent association with an increased risk of preterm birth. Nonsteroidal anti-inflammatory drug use could reversibly reduce fecundability. Concerning lactation, available data on various bDMARDs was reassuring. In male patients, available evidence on methotrexate and most other drugs did not reveal adverse effects on sperm quality or birth outcomes. Cyclophosphamide remains the only drug that causes a dose-dependent irreversible infertility.Conclusions This SLR provides up-to-date evidence to guide the 2024 update of the European Alliance of Associations for Rheumatology recommendations for the use of antirheumatic drugs in reproduction, pregnancy, and lactation.
dc.description.numberOfPages30
dc.description.sponsorshipClinic of Rheumatology and Immunology
dc.description.sponsorshipUniversity Library Bern, Medical Library
dc.identifier.doi10.48620/87901
dc.identifier.pmid40240264
dc.identifier.publisherDOI10.1016/j.ard.2025.02.021
dc.identifier.urihttps://boris-portal.unibe.ch/handle/20.500.12422/210151
dc.language.isoen
dc.publisherBMJ Publishing Group
dc.relation.ispartofAnnals of the Rheumatic Diseases
dc.relation.issn1468-2060
dc.relation.issn0003-4967
dc.subject.ddc600 - Technology::610 - Medicine & health
dc.titleAntirheumatic drugs in reproduction, pregnancy, and lactation: a systematic literature review informing the 2024 update of the EULAR recommendations.
dc.typearticle
dspace.entity.typePublication
dspace.file.typetext
oaire.citation.endPage1590
oaire.citation.startPage1561
oaire.citation.volume84
oairecerif.author.affiliationClinic of Rheumatology and Immunology
oairecerif.author.affiliationUniversity Library Bern, Medical Library
oairecerif.author.affiliationClinic of Rheumatology and Immunology
unibe.contributor.roleauthor
unibe.contributor.roleauthor
unibe.contributor.rolecorresponding author
unibe.description.ispublishedpub
unibe.refereedtrue
unibe.subtype.articlejournal

Files

Original bundle
Now showing 1 - 1 of 1
Name:
1-s2.0-S0003496725008143-main.pdf
Size:
1.14 MB
Format:
Adobe Portable Document Format
File Type:
text
License:
https://creativecommons.org/licenses/by-nc-nd/4.0
Content:
published

Collections